New Lung Cancer Drug Exkivity Receives FDA Approval
September 16, 2021FDA Approves Tivdak for Treatment of Advanced Cervical Cancer
September 20, 2021December 20, 2021 – YusimryTM (adalimumab-aqvh), manufactured by Coherus BioSciences, has been approved as a biosimilar for AbbVie's Humira® (adalimumab).
- Yusimry is indicated to treat juvenile idiopathic arthritis in patients at least two years of age; Crohn's disease in patients at least six years of age; and rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and plaque psoriasis in adults.
- Recommended dosing is based on the indication. Yusimry is given via subcutaneous injection and can be self-administered or administered by a caregiver.
- Coherus BioSciences plans to launch the product in July 2023, in accordance with an agreement with AbbVie. Humira biosimilars for other manufacturers are expected to launch the same year.